fotemustine has been researched along with Melanoma in 141 studies
*Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) [MeSH]
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (1.42) | 18.7374 |
1990's | 65 (46.10) | 18.2507 |
2000's | 44 (31.21) | 29.6817 |
2010's | 27 (19.15) | 24.3611 |
2020's | 3 (2.13) | 2.80 |
Authors | Studies |
---|---|
Bonnet, PA; Bressolle, F; David, N; Deleuze-Masquefa, C; Gayraud-Paniagua, S; Khier, S; Moarbess, G; Pinguet, F | 1 |
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
Alamodi, A; Gomez, CR; Grada, Z; Haikel, Y; Hassan, M; Hassan, SL; Hassan, SY; Jamal, SME; Megahed, M; Murad, F; Santourlidis, S; Shareef, MA; Wahl, RU | 1 |
Bauer, S; Haubold, J; Ludwig, JM; Richly, H; Schaarschmidt, BM; Siveke, JT; Theysohn, JM; Umutlu, L; Wimmer, J | 1 |
Amato, G; Calabrò, L; Camerini, R; Chiarion-Sileni, V; Covre, A; Cutaia, O; Del Vecchio, M; Di Giacomo, AM; Ferrucci, PF; Giannarelli, D; Guida, M; Guidoboni, M; Maio, M; Mandalà, M; Marchetti, P; Quaglino, P; Valente, M | 1 |
Aprea, P; Ascierto, PA; Botti, G; Caracò, C; Cavalcanti, E; Comella, G; Cossu, A; Daponte, A; Gallo, C; Grimaldi, AM; Lastoria, S; Maiorino, L; Massidda, B; Mozzillo, N; Palmieri, G; Petrillo, A; Signoriello, S; Simeone, E | 1 |
Addeo, R; Caraglia, M; Facchini, S; Luce, A; Zappavigna, S | 1 |
Grosso, M; Pesce, M; Picasso, V; Queirolo, P; Spagnolo, F; Tornari, E | 1 |
Berniard, A; Carita, G; de Montrion, C; de Plater, L; Decaudin, D; Depil, S; Desjardins, L; Geneste, O; Kraus-Berthier, L; Lang, G; Lockhart, B; Némati, F; Pierré, A; Piperno-Neumann, S; Sastre-Garau, X; Vallerand, D | 1 |
Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L | 1 |
Baurain, JF; Durando, X; Gurunath, RK; Jouary, T; Kaempgen, E; Keilholz, U; Leyvraz, S; Marshall, E; Negrier, S; Piperno-Neumann, S; Schadendorf, D; Scheulen, M; Suciu, S; Testori, A; Vermorken, JB; Zdzienicki, M | 1 |
Aigner, B; Artl, M; Niederkorn, A; Richtig, E; Schwantzer, G; Wackernagel, W | 1 |
Annesi, D; Ascierto, PA; Calabrò, L; Danielli, R; Del Vecchio, M; Di Giacomo, AM; Fonsatti, E; Giannarelli, D; Guidoboni, M; Maccalli, C; Maio, M; Maurichi, A; Orgiano, L; Parmiani, G; Pilla, L; Queirolo, P; Ridolfi, R; Santinami, M; Simeone, E; Spadola, G; Testori, A | 1 |
Christmann, M; Kaina, B; Krumm, A; Loquai, C; Merz, S; Quiros, S; Roos, WP; Switzeny, OJ | 1 |
Chi, ZH; Cui, CL; Guo, J; Lian, HY; Si, L; Yuan, XQ | 1 |
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I | 1 |
Aitini, E; Ballardini, M; Bichisao, E; Fiorentini, G; Freschi, A; Guida, M; Michiara, M; Ridolfi, L; Ridolfi, R | 1 |
Cuttone, G; Iannolo, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Valastro, LM; Zakula, JJ | 1 |
Ferri-Níguez, B; González-Tortosa, J; Ros de San Pedro, J | 1 |
Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; Gattacceca, F; Khier, S; Margout, D; Moarbess, G; Pinguet, F; Solassol, I | 1 |
Bechrakis, N; Foerster, MH; Keilholz, U; Krössin, M; Lindner, M; Schmittel, A; Schuster, R; Thiel, E; Wacker, F | 1 |
Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S | 1 |
Anichini, A; Bajetta, E; Bedognetti, D; Canova, S; Del Vecchio, M; Di Guardo, L; Morosini, P; Mortarini, R; Perrone, T; Pimpinelli, N; Queirolo, P; Sertoli, MR | 1 |
Colucci, G; Cramarossa, A; Fistola, E; Giudice, G; Guida, M; Lubello, K; Porcelli, M | 1 |
Di Giacomo, AM; Maio, M; Margolin, KA | 1 |
Anastassiou, G; Bornfeld, N; Freistuehler, M; Hilger, RA; Nareyeck, G; Scheulen, ME; Steuhl, KP; Westekemper, H; Zeschnigk, M | 1 |
Cuttone, G; Iannolo, G; Keta, O; Korićanac, L; Petrović, I; Ristić-Fira, A; Žakula, J | 1 |
Amadori, D; Calzolari, F; Farolfi, A; Guidoboni, M; Milandri, C; Ridolfi, L; Ridolfi, R; Scarpi, E | 1 |
Dréno, B; Quéreux, G | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A | 1 |
Auffret, M; Bertrand, M; Gauthier, S; Mortier, L; Wémeau-Stervinou, L | 1 |
Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E | 1 |
Annesi, D; Ascierto, PA; Di Giacomo, AM; Ferrucci, PF; Fonsatti, E; Giannarelli, D; Maio, M; Marasco, A; Nicoletti, SV; Parmiani, G; Pilla, L; Queirolo, P; Ridolfi, R; Rivoltini, L; Santinami, M; Simeone, E; Testori, A | 1 |
Garbe, C | 1 |
Beitzke, D; Berzaczy, D; Edelhauser, G; Funovics, M; Höeller, C; Lammer, J; Schicher, N | 1 |
Campello, C; Meunier, L; Renard, D; Stoebner, P | 1 |
Geissler, A; Gruss, C; Landthaler, M; Schalke, B; Stolz, W | 1 |
Foletto, M; Lise, M; Mocellin, S; Pilati, P; Rossi, CR | 1 |
Becker, JC; Bröcker, EB; Kämpgen, E; Lieb, W; Neumann, C; Schadendorf, D; Steinmann, A; Terheyden, P; Wagner, S; Wittenberg, G | 1 |
Aglione, S; Bajetta, E; Bernard-Marty, C; Buzzoni, R; Del Vecchio, M; Khayat, D; Nova, P; Rixe, O; Taillibert, S; Vitali, M | 1 |
Gschwendt, B; Helmbach, H; Kioschis, P; Korn, B; Lichter, P; Mollenhauer, J; Münstermann, E; Nessling, M; Poustka, A; Salowsky, R; Schadendorf, D; Schick, M; Will, RD; Wittig, R | 1 |
Bensadoun, RJ; Bonneterre, ME; Bourdin, S; Bui, BN; Clavel, M; Cupissol, D; De Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Thomas, L; Tilgen, W; Ulrich, J | 1 |
Dréno, B; Wallon-Dumont, G | 1 |
Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH | 1 |
Bensadoun, JR; Bonneterre, J; Bourdin, S; Clavel, M; Cupissol, D; de Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Nguyen, BB; Thomas, L; Tilgen, W; Ulrich, J | 1 |
Bouissière, JL; Cuq, P; Evrard, A; Montero, JL; Montero, V; Passagne, I; Winum, JY | 1 |
De Salvo, GL; Foletto, M; Lejeune, FJ; Lise, M; Lopes, M; Mocellin, S; Pilati, PL; Pontes, L; Ribeiro, M; Rossi, CR | 1 |
Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Montero, JL; Passagne, I; Vian, L; Winum, JY | 1 |
Aamdal, S; Avril, MF; Bieber, T; Bonerandi, JJ; Bonneterre, J; Fra, J; Gilde, K; Gonzalez Larriba, JL; Grob, JJ; Guillem Porta, V; Hauschild, A; Kamanabrou, D; Menu, Y; Mohr, P; Neuber, K; Pehamberger, H; Saïag, P; Scherrer, A; Sufliarsky, J; Weichenthal, M | 1 |
Eigentler, TK; Garbe, C | 1 |
Friedlander, M; Kurtovic, J; Riordan, SM; Singh-Grewal, I; Webster, GJ | 1 |
Bonenkamp, JJ; de Faria Lima, R; de Wilt, JH; Doubrovsky, A; Kam, PC; Thompson, JF | 1 |
Grange, JD; Kodjikian, L; Rivoire, M | 1 |
Acquati, M; Eggermont, AM; Kirkwood, JM; Queirolo, P; Rocca, A; Testori, A | 1 |
Karpenko, LG | 1 |
Carlander, B; Guillot, B; Khalil, Z; Pageot, N | 1 |
Bosshard, W; Fiorentini, G; Gillet, M; Humblet, Y; Keilholz, U; Leyvraz, S; Lotem, M; Pampallona, S; Peters, S; Piperno-Neumann, S; Popescu, R; Stupp, R; Voelter, V; Weitzen, R; Zografos, L | 1 |
Akimov, MA; Bogdanova, NV; Gershanovich, ML; Konstantinova, MM; Nosov, DA | 1 |
Clerico, MA; Marinozzi, C; Sozzi, P; Turrisi, G | 1 |
Bembenek, A; Hauschild, A; Kähler, KC; Kettelhack, C; Schlag, PM; Siegel, R | 1 |
Cuttone, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Todorović, DV; Valastro, LM | 1 |
Amadori, D; Bonafe, M; Brigliadori, G; Fabbri, F; Rosetti, M; Storci, G; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
Bajetta, E; Canova, S; Del Vecchio, M; Messina, A | 1 |
Gill, S; Prince, HM; Shapiro, J; Westerman, D | 1 |
Camlica, H; Tas, F; Topuz, E | 1 |
Avril, MF | 1 |
Denys, A; Goitein, G; Halkic, N; Leyvraz, S; Pampallona, S; Peters, S; Schalenbourg, A; Voelter, V; Zografos, L | 1 |
Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M | 1 |
Bröcker, EB; Engel, E; Gérard, B; Glabbeke, MV; Israels, P; Kennes, C; Kleeberg, UR; Lejeune, F; Lentz, MA; Tilgen, W | 1 |
Barbé, V; Berlion, M; Berrile, J; Bizzari, JP; Fischel, JL; Formento, P; Milano, G | 2 |
Gerard, B; Punt, CJ; Tytgat, JH; van Liessum, PA | 1 |
A'Hern, R; Atkinson, H; Chang, J; Gore, ME; Lorentzos, A | 1 |
Falkson, CI; Falkson, G; Falkson, HC | 1 |
Berille, J; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Giroux, B; Khayat, D; Sarkany, M | 1 |
Boaziz, C; Breau, JL; Israël, L; Mazeron, JJ; Morere, JF | 1 |
Bureau, B; Célérier, P; Dreno, B; Litoux, P | 1 |
Chaitchik, S; Merimsky, O | 1 |
Aliaga, A; Bizzari, JP; Cour, V; Lopez Lopez, JJ; Oliver, V; Perez, E; Ponchon, A | 1 |
Dougal, M; Lee, SM; Margison, GP; Thatcher, N | 1 |
Aamdal, S; Bizzari, JP; D'Incalci, M; Gerard, B; Lee, SM; Leyvraz, S; Lucas, C | 1 |
Lee, SM; Margison, GP; Thatcher, N; Woodcock, AA | 1 |
Antoine, E; Auclerc, G; Benhammouda, A; Bizzari, JP; Borel, C; Paraiso, D; Petit, T; Rixe, O; Soubrane, C; Weil, M | 1 |
Avril, MF; Borel, C; Giroux, B; Khayat, D; Monnier, A; Petit, T; Rixe, O; Weil, M | 1 |
Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL | 1 |
Anderson, CM; Buzaid, AC; Legha, SS | 1 |
Bohndorf, W; Bröcker, EB; Engenhart, K; Flentje, M; Kämpgen, E; Messer, P; Tilgen, W; Trcka, J | 1 |
Bauer, J; Dorval, T; Gillet, M; Lejeune, F; Leyvraz, S; Meuli, R; Pampallona, S; Salmon, R; Spataro, V; Zografos, L | 1 |
Bartley, J; Eaglesham, GK; Hayes, MT; Parsons, PG; Prakash, AS | 1 |
Caponigro, F; Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Ionna, F; Mozzillo, N; Parziale, AP; Presutti, F | 1 |
Azevedo, MC; Lopes, M; Pontes, L; Ribeiro, M; Santos, JG | 1 |
Altenhoff, J; Breitbart, EW; Hossfeld, DK; Kowalzick, L; Marseille, A; Mohr, P; Sarkany, M; Stephan, U; Weichenthal, M | 1 |
Bartley, J; Hayes, MT; Parsons, PG | 1 |
Asselain, B; Desjardins, L; Dorval, T; Levy, C; Leyvraz, S; Plancher, C; Pouillart, P; Salmon, RJ; Schlienger, P; Servois, V | 1 |
Breitbart, E; Makki, A; Mohr, P; Schadendorf, D | 1 |
Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H | 1 |
Casella, G; di Bonito, M; Fortuna, G; Iodice, F; Stellato, G; Tramontana, R; Tramontana, S | 1 |
Bröcker, EB; Göring, HD; Kämpgen, E; Kröning, Y; Trebing, D; Zierner, A | 1 |
Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F | 1 |
Bonerandi, JJ; Delaunay, M; Grob, JJ; Koeppel, MC; Laurans, R; Murraciole, X; Paul, K; Perragut, JC; Regis, J; Souteyrand, P; Wolkenstein, P | 1 |
Becker, JC; Bröcker, EB; Kämpgen, E; Rünger, TM; Terheyden, P | 1 |
Aamdal, S; Bohmann, T; Gerard, B; Lucas, C; Semb, KA | 1 |
Ablett, E; Dannoy, PA; Parsons, PG; Pedley, J; Sturm, RA | 1 |
Christmann, M; Dietel, M; Kaina, B; Kern, MA; Lage, H; Pick, M; Schadendorf, D | 1 |
Binder, M; Pehamberger, H; Seeber, A; Steiner, A; Wolff, K | 1 |
Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D | 1 |
Comella, P; Daponte, A | 1 |
Gademann, G; Gollnick, H; Ulrich, J | 1 |
Diem, C; Emmert, S; Epe, B; Hellfritsch, D; Rünger, TM; Schadendorf, D | 1 |
Kern, MA; Lichter, P; Nessling, M; Schadendorf, D | 1 |
Becker, JC; Bröcker, EB; Kämpgen, E; Terheyden, P | 1 |
Ascierto, PA; Cellerino, R; Comella, G; Comella, P; Daponte, A; DeLena, M; Gravina, A; Marini, G; Melucci, MT; Palmieri, G | 1 |
Bock, M; Deichmann, M; Jäckel, A; Näher, H; Waldmann, V | 1 |
Christmann, M; Kaina, B; Lage, H; Pick, M; Schadendorf, D | 1 |
Egerer, G; Ho, AD; Keilholz, U; Lehnert, T; Max, R; Naeher, H | 1 |
Berlion, M; Marchal, S; Merlin, JL; Poullain, MG; Ramacci, C | 1 |
Chaitchik, S; Inbar, M; Kovner, F; Merimsky, O; Reider-Groswasser, I | 1 |
Chaitchik, S; Gerard, B; Inbar, M; Merimsky, O | 1 |
Elgren, TE; Hogenkamp, HP; MacFarlan, S; Nelson, LS; Schallreuter, KU; Yan-Sze, I | 1 |
Boaziz, C | 1 |
Avril, MF; Bonneterre, J; Cupissol, D; Fargeot, P; Fumoleau, P; Grob, JJ; Israel, L; Kalis, B; Kerbrat, P; Lambert, D | 1 |
Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K | 1 |
Avril, MF; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Khayat, D | 1 |
Chaitchik, S; Inbar, M; Merimsky, O | 1 |
Aamdal, S; Bohman, T; D'Incalci, M; Gerard, B | 1 |
Ring, J; Schallreuter, KU | 1 |
Berger, J; Brassow, FW; Breitbart, EW; Schallreuter, KU; Teichmann, W; Wenzel, E | 1 |
Breitbart, EW; Mensing, H; Schallreuter, KU; Wood, JM | 1 |
Lee, SM; Margison, GP; Thatcher, N | 1 |
Chaitchik, S; Inbar, M; Merimsky, O; Reider-Groswasser, I | 1 |
Boaziz, C; Breau, JL; Israël, L; Morere, JF | 1 |
Aigner, K; Auclerc, G; Bizzari, JP; Borel, C; Bousquet, JC; Buthiau, D; Cohen-Alloro, G; Cour, V; Khayat, D; Weil, M | 1 |
Aapro, M; Ardizzoni, A; Becquart, D; Calabresi, F; Dirix, L; Gerard, B; Wils, J | 1 |
Schallreuter, KU; Wood, JM | 1 |
Avril, MF; Banzet, P; Bonerandi, JJ; Bonneterre, J; Fumoleau, P; Jacquillat, C; Kerbrat, P; Khayat, D; Namer, M; Weil, M | 2 |
Avril, MF; Bonneterre, J; Bugat, R; Cupissol, D; Delaunay, M; Fumoleua, P; Grosshans, E; Israel, L; Kerbrat, P; Namer, M | 1 |
Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G | 1 |
Beerblock, K; Bizzari, JP; Deloffre, P; Lokiec, F; Lucas, C | 1 |
Banzet, P; Bizzari, JP; Frenay, M; Goupil, A; Jacquillat, C; Khayat, D; Naman, H; Namer, M; Rouesse, J; Weil, M | 1 |
20 review(s) available for fotemustine and Melanoma
Article | Year |
---|---|
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 2013 |
[Cerebellopontine angle meningeal melanocytoma: a benign tumor?].
Topics: Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Cerebellopontine Angle; Diagnosis, Differential; Disease Progression; Fatal Outcome; Gait Disorders, Neurologic; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neurilemmoma; Nevus; Nitrosourea Compounds; Organophosphorus Compounds | 2009 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Italy; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Temozolomide; United States | 2010 |
Fotemustine for the treatment of melanoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Melanoma; Molecular Structure; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 2011 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2013 |
Isolated limb perfusion in locally advanced cutaneous melanoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Genetic Therapy; Humans; Melanoma; Melphalan; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Reproducibility of Results; Skin Neoplasms; Tumor Necrosis Factor-alpha | 2002 |
Metastatic melanoma: chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Cytokines; Dacarbazine; Genetic Therapy; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Tamoxifen; Taxoids; Thalidomide | 2002 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Forecasting; Humans; Immunization, Passive; Immunotherapy; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Temozolomide; Time Factors | 2003 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine | 2004 |
Update: current management issues in malignant melanoma.
Topics: Chemotherapy, Adjuvant; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 2005 |
Fotemustine in the treatment of brain primary tumors and metastases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Glioma; Humans; Lung Neoplasms; Melanoma; Middle Aged; Multicenter Studies as Topic; Nitrosourea Compounds; Organophosphorus Compounds | 1994 |
[Malignant melanoma of the uvea].
Topics: Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Eye Enucleation; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Uveal Neoplasms | 1993 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 1995 |
[Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature].
Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Treatment Outcome; Uveal Neoplasms | 1998 |
[Therapy of metastatic malignant uveal melanoma].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoembolization, Therapeutic; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Skin Neoplasms; Time Factors; Uveal Neoplasms | 2001 |
[Contribution of a new nitrosourea compound: fotemustine].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dacarbazine; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1992 |
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine | 1992 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Semustine | 1991 |
Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction | 1991 |
45 trial(s) available for fotemustine and Melanoma
Article | Year |
---|---|
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Time Factors; Young Adult | 2021 |
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Analysis | 2013 |
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Uveal Neoplasms; Young Adult | 2014 |
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Brain Neoplasms; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Skin Neoplasms; Survival Rate | 2015 |
[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokine-Induced Killer Cells; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatic Artery; Humans; Immunotherapy, Adoptive; Infusions, Intra-Arterial; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Survival Rate; Thrombocytopenia; Young Adult | 2008 |
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Salvage Therapy; Skin Neoplasms; Survival Analysis | 2009 |
Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Topics: Adult; Aged; Angiogenic Proteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cells, Cultured; Female; Humans; Lymphangiogenesis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Young Adult | 2010 |
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Hematologic Diseases; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 2012 |
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Hepatic Artery; Humans; Immunotherapy; Infusions, Intra-Arterial; Interferon-alpha; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Rate; Treatment Outcome; Uveal Neoplasms | 2002 |
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome | 2003 |
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Female; Humans; Life Tables; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 2003 |
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Skin Neoplasms; Statistics, Nonparametric; Survival Analysis | 2004 |
[Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2005 |
Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Eye Neoplasms; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Analysis | 2007 |
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2008 |
Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Risk; Secondary Prevention; Survival Analysis; Uveal Neoplasms | 2008 |
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Treatment Outcome | 1995 |
Fotemustine and tamoxifen combination therapy in metastatic malignant melanoma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Tamoxifen | 1995 |
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Outcome | 1994 |
Phase II trial of fotemustine in patients with metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Failure | 1994 |
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome; Thrombocytopenia | 1993 |
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine | 1995 |
Complete remission seven years after treatment for metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease-Free Survival; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Splenic Neoplasms | 1996 |
Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Radiotherapy Dosage; Treatment Outcome | 1996 |
Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Catheters, Indwelling; Eye Neoplasms; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 1997 |
Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Rate | 1997 |
Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms | 1997 |
Fotemustine and interferon alpha2b in metastatic malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Treatment Outcome | 1998 |
Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Drug Administration Schedule; Humans; Leukopenia; Melanoma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms; Thrombocytopenia | 1998 |
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Glioma; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 1998 |
Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Tamoxifen; Time Factors | 1998 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide | 1999 |
Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Skin Neoplasms; Survival Rate | 2000 |
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Topics: Adult; Aged; Anemia; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Dacarbazine; Female; Fever; Follow-Up Studies; Humans; Interferon-alpha; Male; MART-1 Antigen; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Nausea; Neoplasm Proteins; Neural Cell Adhesion Molecules; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2000 |
Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients.
Topics: Adult; Antineoplastic Agents; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Treatment Outcome; Uveal Neoplasms | 2001 |
Fotemustine--an advance in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1992 |
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine | 1992 |
Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Remission Induction | 1992 |
Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction | 1991 |
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1991 |
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 1990 |
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 1990 |
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Tomography, X-Ray Computed | 1990 |
78 other study(ies) available for fotemustine and Melanoma
Article | Year |
---|---|
New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Quinoxalines; Structure-Activity Relationship | 2009 |
Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways.
Topics: AC133 Antigen; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Stem Cells | 2020 |
Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Biomarkers, Tumor; Blood Platelets; C-Reactive Protein; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocytes; Male; Melanoma; Melphalan; Middle Aged; Neutrophils; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Tumor Burden; Uveal Neoplasms | 2021 |
Treatment of metastatic uveal melanoma with intravenous fotemustine.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Rate; Treatment Outcome; Uveal Neoplasms | 2013 |
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Proliferation; Fluorescence Polarization; Heterocyclic Compounds, 3-Ring; Humans; Immunohistochemistry; Melanoma; Mice; Mice, SCID; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Nitrosourea Compounds; Organophosphorus Compounds; Peptides; Protein Binding; Sulfonamides; Survival Analysis; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Uveal Neoplasms | 2014 |
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Humans; Indoles; Melanoma; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib | 2009 |
Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.
Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Protons | 2009 |
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Imiquimod; Injections, Intraperitoneal; Injections, Intravenous; Male; Melanoma; Mice; Mice, Nude; Nitrosourea Compounds; Organophosphorus Compounds; Quinoxalines; Rats; Skin Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoembolization, Therapeutic; Cisplatin; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome; Uveal Neoplasms | 2010 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Mice; Mice, SCID; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Oligonucleotide Array Sequence Analysis; Organophosphorus Compounds; Polymorphism, Single Nucleotide; Temozolomide; Tumor Cells, Cultured; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2010 |
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2010 |
Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Conjunctival Neoplasms; Humans; Melanoma; Mitomycin; Nitrosourea Compounds; Organophosphorus Compounds; Tretinoin | 2011 |
Proton inactivation of melanoma cells enhanced by fotemustine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Proton Therapy; Radiation Tolerance; Radiotherapy, Conformal | 2011 |
Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Drug Delivery Systems; Drug Monitoring; Electronic Health Records; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis; Uveal Neoplasms; Young Adult | 2011 |
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome | 2011 |
[New toxicity of fotemustine: diffuse interstitial lung disease].
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lung Diseases, Interstitial; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 2012 |
Ipilimumab with fotemustine in metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Ipilimumab; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 2012 |
Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis.
Topics: Adult; Aged; Antineoplastic Agents; Chemoembolization, Therapeutic; Contrast Media; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Uveal Neoplasms | 2012 |
Fotemustine-related leukoencephalopathy.
Topics: Aged; Antineoplastic Agents; Brain; Female; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Tomography Scanners, X-Ray Computed | 2013 |
Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation.
Topics: Antineoplastic Agents, Alkylating; Atrophy; Brain; Brain Damage, Chronic; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dementia; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Quality of Life; Radiotherapy, High-Energy; Remission Induction | 2002 |
Candidate genes for cross-resistance against DNA-damaging drugs.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Cisplatin; Cluster Analysis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Tumor Cells, Cultured | 2002 |
Topical imiquimod in the treatment of metastatic melanoma to skin.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome | 2003 |
Synthesis and biological evaluation of Fotemustine analogues on human melanoma cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, Thin Layer; Colony-Forming Units Assay; Coloring Agents; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Magnetic Resonance Spectroscopy; Melanoma; Neutral Red; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds | 2003 |
Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
Topics: Antineoplastic Agents; Apoptosis; Carmustine; DNA Damage; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Guanine; Humans; Melanoma; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Tumor Cells, Cultured | 2003 |
Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment.
Topics: Acetylcysteine; Adult; Antineoplastic Agents; Antioxidants; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Treatment Outcome | 2004 |
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Follow-Up Studies; Humans; Limb Salvage; Lower Extremity; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 2004 |
Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Fatal Outcome; Female; Follow-Up Studies; Hepatectomy; Humans; Injections, Intra-Arterial; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Time Factors; Uveal Neoplasms | 2005 |
[Experience with use of mustoforan at the Clinical Oncological Dispensary of the Republic of Tatarstan].
Topics: Antineoplastic Agents; Cancer Care Facilities; Disease Progression; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Russia; Skin Neoplasms; Treatment Outcome | 2005 |
Neurological toxicity during metastatic melanoma treatment with fotemustine.
Topics: Antineoplastic Agents; Brain Neoplasms; Female; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 2005 |
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Uveal Neoplasms | 2006 |
Persistent thrombocytopenia during melanoma treatment with fotemustine.
Topics: Aged; Antineoplastic Agents; Humans; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 2006 |
Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Proton Therapy | 2007 |
Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine.
Topics: Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Cisplatin; DNA Mutational Analysis; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Tumor Suppressor Protein p53 | 2007 |
Impressive objective response in a patient with extensive metastatic melanoma including the brain.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Female; Humans; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed | 2007 |
Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Tomography, X-Ray Computed | 2007 |
[Fotemustine: muphoran].
Topics: Antineoplastic Agents; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 2007 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine | 1994 |
[Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; In Vitro Techniques; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1994 |
Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1993 |
[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1993 |
Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1993 |
Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction | 1993 |
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
Topics: Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Humans; Leukocytes, Mononuclear; Melanoma; Methyltransferases; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds | 1993 |
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Lung; Lung Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome | 1993 |
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1995 |
Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity.
Topics: Antineoplastic Agents; Cell Survival; DNA Adducts; DNA Methylation; DNA Repair; Dose-Response Relationship, Drug; Drug Stability; Guanine; HeLa Cells; Humans; Mass Spectrometry; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Tumor Cells, Cultured | 1997 |
In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma.
Topics: Adenoviridae; Antineoplastic Agents; Carcinogens; Cell Cycle; Cell Survival; DNA, Neoplasm; Drug Evaluation; Humans; Hyperthermia, Induced; Melanoma; Methylnitronitrosoguanidine; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Perfusion; Skin Neoplasms; Tumor Cells, Cultured; Virus Replication | 1998 |
Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome; Uveal Neoplasms | 1998 |
Primary malignant melanoma of the vagina: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lymph Node Excision; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Vaginal Neoplasms | 1998 |
Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
Topics: Allergens; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dermatitis, Allergic Contact; Dinitrochlorobenzene; Humans; Immunotherapy; Irritants; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms | 1998 |
Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancérologie Cutanée.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 1998 |
UVB-specific regulation of gene expression in human melanocytic cells: cell cycle effects and implication in the generation of melanoma.
Topics: Antineoplastic Agents; beta-Galactosidase; Cell Cycle; Cisplatin; Demecolcine; Genes, fos; Genes, p53; HeLa Cells; HIV Long Terminal Repeat; Humans; Hydroxyurea; Inosine; Melanocytes; Melanoma; Methylnitronitrosoguanidine; Neoplasms, Radiation-Induced; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins c-fos; Recombinant Proteins; Skin Neoplasms; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured; Ultraviolet Rays | 1998 |
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carrier Proteins; Cisplatin; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; Drug Resistance, Multiple; Etoposide; Humans; Melanoma; MutL Protein Homolog 1; MutS Homolog 2 Protein; N-Glycosyl Hydrolases; Neoplasm Proteins; Nitrosourea Compounds; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins; RNA, Messenger; Transcription, Genetic; Vindesine | 1999 |
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1998 |
Comments on: Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine, Seeber, et al., Eur J Cancer 1998, 34, 2129-2131.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1999 |
Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis | 1999 |
Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; DNA Repair; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Melanoma; Microsatellite Repeats; Nitrosourea Compounds; Organophosphorus Compounds; Oxygen; Tumor Cells, Cultured; Ultraviolet Rays | 2000 |
Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines.
Topics: Aneuploidy; Antineoplastic Agents; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 9; Cisplatin; DNA Mutational Analysis; DNA Probes; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Etoposide; Genome, Human; Humans; Melanoma; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Selection, Genetic; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Vindesine | 1999 |
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Topics: Antineoplastic Agents; Azacitidine; Blotting, Southern; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Enzyme Reactivators; Gene Amplification; Gene Expression; Guanine; Humans; Melanoma; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Promoter Regions, Genetic; Tumor Cells, Cultured | 2001 |
Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Drug Synergism; Humans; Inhibitory Concentration 50; Melanoma; Mercaptoethylamines; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Radiation-Protective Agents; Tumor Cells, Cultured | 2002 |
Cerebral metastatic melanoma: correlation between clinical and CT findings.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed | 1992 |
Ribonucleotide diphosphate reductase from human metastatic melanoma.
Topics: Antineoplastic Agents; Cell-Free System; Electron Spin Resonance Spectroscopy; Humans; Hydroxyurea; Kinetics; Macromolecular Substances; Melanoma; Models, Structural; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Ribonucleoside Diphosphate Reductase | 1992 |
Fotemustine plus dacarbazine for malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pneumonia | 1992 |
A probable mechanism for hyperpigmentation by fotemustine.
Topics: Antineoplastic Agents; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Pigmentation Disorders; Thioredoxin-Disulfide Reductase | 1992 |
Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Time Factors | 1991 |
Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Injections, Intralesional; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1991 |
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
Topics: Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Lymphocytes; Male; Melanoma; Methyltransferases; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds | 1991 |
Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 1991 |
Sensitivity and resistance in human metastatic melanoma to the new chloroethylnitrosourea anti-tumor drug Fotemustine.
Topics: Antineoplastic Agents; Cell Membrane; Chromatography, High Pressure Liquid; Drug Resistance; Glutathione Reductase; Humans; Kinetics; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Thioredoxin-Disulfide Reductase | 1991 |
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Topics: Antineoplastic Agents; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1990 |
In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Topics: Antineoplastic Agents; Carmustine; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Thymidine; Tumor Cells, Cultured | 1990 |
[Study of the clinical pharmacokinetics of fotemustine in various tumor indications].
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds | 1989 |
Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma.
Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1988 |